Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of Novel Isofunctional SARS-CoV‑2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening.

ACS medicinal chemistry letters·2025
Same author

Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors.

Journal of medicinal chemistry·2025
Same author

Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase.

Nature·2024
Same author

How Entering Students View Nursing as a Profession After COVID-19: A Qualitative Study.

Nursing education perspectives·2023
Same author

In vivo PAR-CLIP (viP-CLIP) of liver TIAL1 unveils targets regulating cholesterol synthesis and secretion.

Nature communications·2023
Same author

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells.

Scientific reports·2022

Related Experiment Video

Updated: May 3, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

11.9K

Stabilized Interleukin-6 receptor binding RNA aptamers.

Cindy Meyer1, Katharina Berg2, Katja Eydeler-Haeder2

  • 1Laboratory of RNA Molecular Biology; Howard Hughes Medical Institute; The Rockefeller University; New York, NY USA.

RNA Biology
|January 21, 2014
PubMed
Summary

Researchers developed stabilized RNA aptamers targeting the Interleukin-6 receptor (IL-6R) for potential use in treating IL-6-dependent inflammatory diseases and cancers like multiple myeloma and hepatocellular carcinoma.

Keywords:
AptamersHyper-IL-6Interleukin-6 receptorRNARNA-protein interactionSELEXpost-selective modification

More Related Videos

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

19.0K
Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

5.8K

Related Experiment Videos

Last Updated: May 3, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

11.9K
An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

19.0K
Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
11:34

Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

Published on: August 9, 2019

5.8K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Interleukin-6 (IL-6) is a key cytokine in inflammatory diseases and cancers.
  • Targeting the IL-6 receptor (IL-6R) on tumor cells with aptamers is a potential therapeutic strategy.
  • Previous RNA aptamers showed nanomolar affinity but were susceptible to degradation in vivo.

Purpose of the Study:

  • To generate stabilized RNA aptamers for targeting the IL-6 receptor (IL-6R).
  • To assess the binding affinity and functionality of these modified aptamers for potential in vivo applications.
  • To advance therapeutic strategies for IL-6-dependent diseases.

Main Methods:

  • Selection and modification of RNA aptamers targeting human IL-6 receptor (IL-6R).
  • Chemical modification using 2'-F to enhance stability against ribonucleases.
  • Assessment of binding affinity and interference with IL-6 receptor complex formation.

Main Results:

  • Generated stabilized RNA aptamers with low nanomolar binding affinity to IL-6R.
  • The 2'-F-modified aptamers bind to the extracellular portion of IL-6R.
  • Aptamers did not impede IL-6 receptor complex formation, maintaining natural signaling pathways.

Conclusions:

  • Stabilized RNA aptamers targeting IL-6R offer a promising avenue for in vivo applications.
  • These aptamers represent a step towards developing new treatments for IL-6-driven diseases.
  • Potential applications include multiple myeloma and hepatocellular carcinoma therapy.